bevacizumab

Conference Coverage

Atezolizumab Plus Bevacizumab Unlikely to be Cost-Effective Compared With Sorafenib for HCC

01/15/2021

Journal of Clinical Pathways

Research in Review

Switching From Docetaxel to Paclitaxel and Bevacizumab Improves PFS in NSCLC

12/08/2016

JCP Editors

Patients with non-squamous non-small cell lung cancer (NSCLC) have improved progression-free survival (PFS) if they switch from docetaxel to paclitaxel and bevacizumab treatments, according to new...

...

12/08/2016

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

See Full Calendar

bevacizumab

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products